Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2147622rdf:typepubmed:Citationlld:pubmed
pubmed-article:2147622lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:2147622lifeskim:mentionsumls-concept:C0007820lld:lifeskim
pubmed-article:2147622lifeskim:mentionsumls-concept:C0040162lld:lifeskim
pubmed-article:2147622pubmed:issue3-4lld:pubmed
pubmed-article:2147622pubmed:dateCreated1991-1-24lld:pubmed
pubmed-article:2147622pubmed:abstractTextEffects of protirelin tartrate, administered for 14 days (2 mg/day, i.m.) to 15 patients with acute cerebrovascular disease have been investigated. The evaluation was performed by means of SPECT, at enrollment and at the end of treatment. This evaluation was aimed at the early detection of ischemic damage and assessment of the size of the hypoperfusion area. Treatment with protirelin tartrate was well tolerated and led to definite improvement of the scintigraphic findings in about 74% of the patients.lld:pubmed
pubmed-article:2147622pubmed:languageitalld:pubmed
pubmed-article:2147622pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2147622pubmed:citationSubsetIMlld:pubmed
pubmed-article:2147622pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2147622pubmed:statusMEDLINElld:pubmed
pubmed-article:2147622pubmed:issn0009-9074lld:pubmed
pubmed-article:2147622pubmed:authorpubmed-author:CostaRRlld:pubmed
pubmed-article:2147622pubmed:authorpubmed-author:ScaffidiAAlld:pubmed
pubmed-article:2147622pubmed:authorpubmed-author:CirrincioneMMlld:pubmed
pubmed-article:2147622pubmed:authorpubmed-author:ChinniciMMlld:pubmed
pubmed-article:2147622pubmed:issnTypePrintlld:pubmed
pubmed-article:2147622pubmed:volume134lld:pubmed
pubmed-article:2147622pubmed:ownerNLMlld:pubmed
pubmed-article:2147622pubmed:authorsCompleteYlld:pubmed
pubmed-article:2147622pubmed:pagination205-9lld:pubmed
pubmed-article:2147622pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2147622pubmed:meshHeadingpubmed-meshheading:2147622-...lld:pubmed
pubmed-article:2147622pubmed:meshHeadingpubmed-meshheading:2147622-...lld:pubmed
pubmed-article:2147622pubmed:meshHeadingpubmed-meshheading:2147622-...lld:pubmed
pubmed-article:2147622pubmed:meshHeadingpubmed-meshheading:2147622-...lld:pubmed
pubmed-article:2147622pubmed:meshHeadingpubmed-meshheading:2147622-...lld:pubmed
pubmed-article:2147622pubmed:meshHeadingpubmed-meshheading:2147622-...lld:pubmed
pubmed-article:2147622pubmed:meshHeadingpubmed-meshheading:2147622-...lld:pubmed
pubmed-article:2147622pubmed:meshHeadingpubmed-meshheading:2147622-...lld:pubmed
pubmed-article:2147622pubmed:meshHeadingpubmed-meshheading:2147622-...lld:pubmed
pubmed-article:2147622pubmed:meshHeadingpubmed-meshheading:2147622-...lld:pubmed
pubmed-article:2147622pubmed:meshHeadingpubmed-meshheading:2147622-...lld:pubmed
pubmed-article:2147622pubmed:meshHeadingpubmed-meshheading:2147622-...lld:pubmed
pubmed-article:2147622pubmed:articleTitle[Protirelin in the treatment of cerebrovascular disorders].lld:pubmed
pubmed-article:2147622pubmed:affiliationCattedra di Fisiopatologia Medica, Università degli Studi di Palermo.lld:pubmed
pubmed-article:2147622pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2147622pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:2147622pubmed:publicationTypeEnglish Abstractlld:pubmed